<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dihydroergotamine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dihydroergotamine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dihydroergotamine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9363" href="/d/html/9363.html" rel="external">see "Dihydroergotamine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12383" href="/d/html/12383.html" rel="external">see "Dihydroergotamine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708702"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Concurrent drug therapy: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and life-threatening peripheral ischemia have been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F160464"><span class="drugH1">Brand Names: US</span>
<ul>
<li>D.H.E. 45 [DSC];</li>
<li>Migranal;</li>
<li>Trudhesa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866601"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>DHE;</li>
<li>Migranal</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057876"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Alpha-Adrenergic Blocking Agent, Intranasal</span>;</li>
<li>
<span class="list-set-name">Alpha-Adrenergic Blocking Agent, Parenteral</span>;</li>
<li>
<span class="list-set-name">Antimigraine Agent</span>;</li>
<li>
<span class="list-set-name">Ergot Alkaloid and Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812503"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e6522e8-c1db-4527-b456-1d19e61e92e3">Migraine, intractable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, intractable (&gt;72 hours) (status migrainosus):</b> Limited data available; optimal dose not established. Dosing presented as fixed doses (mg) and weight-directed doses (mg/<b>kg</b>); use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Adolescents: Intranasal: 1 spray (0.5 mg) into each nostril (total dose: 1 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2016'])">Ref</a></span>); adult data suggests that dose should be repeated after 15 minutes for a total of 4 sprays (2 mg); maximum daily dose: 6 sprays (3 mg)/24-hour period; <b>Note:</b> Do not exceed 8 sprays (4 mg)/week.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: <b>Note:</b> Premedicate with antiemetic 30 minutes prior to IV dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22049203','lexi-content-ref-25617222','lexi-content-ref-34105158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22049203','lexi-content-ref-25617222','lexi-content-ref-34105158'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low-dose regimen</i>: <b>Note:</b> Improvement usually seen after 5 doses; some experts recommend administering 1 additional dose after headache subsides. If no improvement noted after 5 doses, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7843951','lexi-content-ref-25617222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7843951','lexi-content-ref-25617222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;10 years: IV: 0.1 mg <b>every 6 hours</b>; continue therapy until headache-free up to a maximum of 16 doses per episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7843951','lexi-content-ref-20842580','lexi-content-ref-25617222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7843951','lexi-content-ref-20842580','lexi-content-ref-25617222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 10 to 12 years: IV: 0.15 mg <b>every 6 hours</b>; continue therapy until headache-free up to a maximum of 16 doses per episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7843951','lexi-content-ref-20842580','lexi-content-ref-25617222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7843951','lexi-content-ref-20842580','lexi-content-ref-25617222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≤16 years: IV: 0.2 mg <b>every 6 hours</b>; continue therapy until headache-free up to a maximum of 16 doses per episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7843951','lexi-content-ref-20842580','lexi-content-ref-25617222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7843951','lexi-content-ref-20842580','lexi-content-ref-25617222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High-dose regimen</i>: <b>Note: </b>Improvement usually seen after 5 doses. If no improvement after 5 doses, discontinue therapy. Some experts recommend using an initial test dose (half of the appropriate dose for age and weight) for the first 1 to 2 doses; if test dose(s) tolerated, administer remainder of dose 30 minutes later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19125879','lexi-content-ref-34105158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19125879','lexi-content-ref-34105158'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to 9 years or Children ≥10 years weighing &lt;25 kg: IV: 0.5 mg <b>every 8 hours</b>; if improvement noted, continue therapy until headache-free up to a maximum of 20 doses per episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19125879','lexi-content-ref-26517974','lexi-content-ref-26788131','lexi-content-ref-20842580','lexi-content-ref-25617222','lexi-content-ref-34105158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19125879','lexi-content-ref-26517974','lexi-content-ref-26788131','lexi-content-ref-20842580','lexi-content-ref-25617222','lexi-content-ref-34105158'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years weighing &gt;25 kg and Adolescents: IV: 1 mg <b>every 8 hours</b>; if improvement noted, continue therapy until headache-free up to a maximum of 20 doses per episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19125879','lexi-content-ref-26517974','lexi-content-ref-26788131','lexi-content-ref-20842580','lexi-content-ref-25617222','lexi-content-ref-26790849','lexi-content-ref-34105158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19125879','lexi-content-ref-26517974','lexi-content-ref-26788131','lexi-content-ref-20842580','lexi-content-ref-25617222','lexi-content-ref-26790849','lexi-content-ref-34105158'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Inpatient</i>
<i> infusion regimen (for refractory headache)</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22049203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22049203'])">Ref</a></span>): <b>Note: </b>Optimal benefit seen with 5-day admission for cumulative therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight &lt;50 kg: Dose (mg) = (adolescent dose in mg) (weight in kg) (0.014)</p>
<p style="text-indent:-2em;margin-left:12em;">Day 1: First dose: IV: 0.007 mg/<b>kg</b> over 1 hour; if tolerated, after 8 hours administer second dose of 0.0105 mg/<b>kg</b> over 1 hour.</p>
<p style="text-indent:-2em;margin-left:12em;">Days 2 to 5: Third and subsequent doses: IV: 0.014 mg/<b>kg</b> over 1 hour every 8 hours for 10 doses.</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight ≥50 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">Day 1: First dose: IV: 0.5 mg over 1 hour; if tolerated, then increase dose to second dose 8 hours later of 0.75 mg over 1 hour on Day 1.</p>
<p style="text-indent:-2em;margin-left:12em;">Days 2 to 5: Third and subsequent doses: IV: 1 mg over 1 hour every 8 hours for 10 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents &gt;16 years:</p>
<p style="text-indent:-2em;margin-left:10em;">Day 1: First dose: IV: 0.5 mg over 1 hour; if tolerated, then increase dose to second dose 8 hours later of 0.75 mg over 1 hour on Day 1.</p>
<p style="text-indent:-2em;margin-left:10em;">Days 2 to 5: Third and subsequent doses: IV: 1 mg over 1 hour every 8 hours for 10 doses with the goal of a cumulative total dosage of 11.25 mg.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729694"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Contraindicated in severe renal impairment</p></div>
<div class="block dohp drugH1Div" id="F52729695"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Dosage reductions are most likely necessary but specific guidelines are not available; contraindicated in severe hepatic dysfunction</p></div>
<div class="block doa drugH1Div" id="F160468"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9363" href="/d/html/9363.html" rel="external">see "Dihydroergotamine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Safety:</b> Do <b>not</b> use within 24 hours of triptans or another ergotamine preparation. Screen patients for risk factors for coronary artery disease (CAD); perform a cardiovascular evaluation in patients with CAD risk factors being initiated on dihydroergotamine injection or nasal spray (0.5 mg per spray). Perform cardiovascular evaluation regardless of CAD risk factors in patients initiated on nasal spray (0.725 mg per spray). If evaluation reveals coronary artery vasospasm or myocardial ischemia, do not initiate therapy. If evaluation does not reveal coronary artery or ischemic myocardial disease, administer the first dose in an adequately equipped facility, unless the patient has previously received dihydroergotamine without cardiovascular complications. Obtain an ECG immediately following the first dose in patients with CAD risk factors. Limit use to &lt;10 days per month to avoid medication-overuse headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cb4bef1-d180-4d08-bb54-a66edf4aa19a">Cluster headache</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cluster headache:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM/SUBQ:</b> 1 mg as a single dose; may repeat hourly as needed. Maximum: 3 mg per 24 hours, 6 mg/week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 mg as a single dose; may repeat hourly as needed. Maximum: 2 mg per 24 hours; 6 mg/week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aca50e00-092e-47e7-ab4f-a4a3713385c0">Medication-overuse headache or intractable migraine/status migrainosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Medication-overuse headache or intractable migraine/status migrainosus (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For medication-overuse headache, use in inpatient setting when patients are unlikely to be successful with discontinuing the overused medication along with rescue therapy and preventive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Garza.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Garza.1'])">Ref</a></span>). Premedicate with metoclopramide for nausea; during therapy, administer metoclopramide as needed for nausea, diphenoxylate with atropine as needed for diarrhea, and benztropine as needed for akathisia or dystonic reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9100396','lexi-content-ref-2272823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9100396','lexi-content-ref-2272823'])">Ref</a></span>). Dosing regimens may vary based on institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent infusion (Raskin protocol): <b>IV:</b> Initial: 0.5 mg; subsequent dosing is titrated based on response and tolerability (range: 0.2 to 1 mg) every 8 hours for up to 7 days. Most patients will be headache free within 3 days. If headache persists without nausea following initial dose, a second dose of 0.5 mg may be given in 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9100396','lexi-content-ref-3520384','lexi-content-ref-2272823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9100396','lexi-content-ref-3520384','lexi-content-ref-2272823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion (Ford protocol): <b>IV:</b> 3 mg in 1 L of NS at 42 mL/hour for up to 7 days. Most patients will be headache free within 3 days. If significant nausea persists, decrease rate to 21 to 30 mL/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9100396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9100396'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 1 mg as a single dose; may repeat hourly as needed. Maximum: 3 mg per 24 hours, 6 mg/week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 mg as a single dose; may repeat hourly as needed. Maximum: 2 mg per 24 hours; 6 mg/week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">0.5 mg per spray: 1 spray (0.5 mg) into each nostril; repeat after 15 minutes (total of 4 sprays per dose). Maximum: 4 sprays (1 dose) per 24 hours; safety of doses &gt;8 sprays (2 doses)/week has not been established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8970458','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8970458','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">0.725 mg per spray: 1 spray (0.725 mg) into each nostril (total of 2 sprays per dose); may repeat as needed after ≥1 hour for a total of 4 sprays (2 doses). Maximum: 4 sprays (2 doses) per 24 hours; 6 sprays (3 doses) per 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34363701','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34363701','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 1 mg as a single dose; if symptoms persist, may repeat dose after ≥2 hours. Maximum: 3 mg per 24 hours, 6 mg/week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8639069','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8639069','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991066"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988322"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F160433"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for nasal spray in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local irritation (30% to 52%; including altered sense of smell, burning sensation of the nose, dry nose, epistaxis, nasal cavity pain, nasal congestion, nasal discomfort, nasal mucosa irritation, nasal sore, nasopharyngitis, otalgia, rhinorrhea, sinus discomfort, sinusitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (26%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (injection, intranasal: ≤2%), dysgeusia (8%), nausea (10%), vomiting (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (1%), dizziness (injection, intranasal: ≤4%), drowsiness (3%), paresthesia (injection, intranasal: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Stiffness (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, coronary artery vasospasm, flushing, hypertension, ischemic heart disease, peripheral ischemia, vasospasm, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colonic ischemia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Retroperitoneal fibrosis (prolonged use)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, cerebral hemorrhage, cerebrovascular accident, headache, subarachnoid hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, fibrothorax (prolonged use)</p></div>
<div class="block coi drugH1Div" id="F160447"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to dihydroergotamine, ergot alkaloids, or any component of the formulation; uncontrolled hypertension, ischemic heart disease, angina pectoris, history of MI, silent ischemia, or coronary artery vasospasm including Prinzmetal angina; peripheral vascular disease; sepsis; severe hepatic or renal dysfunction; following vascular surgery; avoid use within 24 hours of 5-hydroxytryptamine-1 (5-HT<sub>1</sub>) receptor agonists (triptans), other serotonin agonists, or ergotamine-containing or ergot-like agents; concurrent use of peripheral and central vasoconstrictors; concurrent use of potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); pregnancy, breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection, nasal spray (0.5 mg per spray):</b> Additional contraindications: Hemiplegic migraine or migraine with brainstem aura (basilar migraine).</p></div>
<div class="block war drugH1Div" id="F160430"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac valvular fibrosis: Dihydroergotamine has been associated with cardiac valvular fibrosis; usually associated with long-term, frequent use or in combination with other medications associated with cardiac valvular fibrosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Adverse cardiac events, including acute myocardial infarction, life-threatening disturbance of cardiac rhythm, and death have been rarely reported following use of dihydroergotamine. May cause vasospastic reactions associated with symptoms of muscle pains, numbness, coldness, pallor, and cyanosis of the digits; myocardial, colonic, and peripheral vascular ischemia have been reported. In patients with compromised circulation, persistent vasospasm may result in gangrene or death. Evaluate patients who experience signs or symptoms suggestive of angina following administration for the presence of coronary artery disease (CAD) or a predisposition to variant angina before receiving additional doses. Similarly, evaluate patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud syndrome. Discontinue therapy if patients develop symptoms of vasoconstriction. Significant hypertension has been reported (rarely) in patient with and without a history of hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular events: Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred (in some cases resulted in fatalities) following use of dihydroergotamine. Discontinue therapy if a cerebrovascular event is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Screen patients for risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, postmenopausal patients, males who are &gt;40 years of age) prior to initiation of therapy; perform a cardiovascular evaluation in patients with CAD risk factors being initiated on dihydroergotamine injection or 0.5 mg/spray nasal spray. Perform cardiovascular evaluation regardless of CAD risk factors in patients initiated on 0.725 mg/spray nasal spray. If evaluation reveals coronary artery vasospasm or myocardial ischemia, do not initiate therapy. If evaluation does not reveal coronary artery disease, ischemic myocardial disease, or other significant cardiovascular disease, administer the first dose in an adequately equipped facility unless the patient has previously received dihydroergotamine without cardiovascular complications. ECG monitoring is recommended in patients with CAD risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nasal spray: Local irritation to nose and throat (usually transient and mild to moderate in severity) can occur; long-term consequences on nasal or respiratory mucosa have not been extensively evaluated (Smith 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>
<i>Other warnings and precautions</i></b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Exacerbation of headache may occur with the overuse (≥10 days per month) of acute migraine drugs; may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Patients may require detoxification and treatment of withdrawal symptoms.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878426"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause nausea; in pediatric patients, antiemetic prophylaxis 30 minutes prior to dihydroergotamine doses is recommended (Srouji 2021).</p></div>
<div class="block dosfc drugH1Div" id="F23082980"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Migranal and Trudhesa nasal solutions contain caffeine 10 mg/mL and dextrose 50 mg/mL.</p></div>
<div class="block foc drugH1Div" id="F160440"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Nasal, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trudhesa: 0.725 mg/actuation (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">D.H.E. 45: 1 mg/mL (1 mL [DSC]) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Migranal: 4 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F160426"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F160448"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Trudhesa Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.725 mg/ACT (per mL): $281.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dihydroergotamine Mesylate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $82.88 - $199.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dihydroergotamine Mesylate Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $65.99 - $514.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Migranal Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $573.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866602"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Migranal: 4 mg/mL (1 mL)</p></div>
<div class="block accres drugH1Div" id="F56687334"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Trudhesa nasal spray is available exclusively through Trudhesa Direct via Phil and Carepoint Pharmacy. Further information is available at https://www.trudhesahcp.com/how-to-prescribe/.</p></div>
<div class="block admp drugH1Div" id="F52612565"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Adolescents: Prior to administration, the nasal spray applicator must be primed (pumped 4 times); in order to let the drug be absorbed through the skin in the nose, avoid deep inhalation through the nose while spraying or immediately after spraying; do not tilt head back. For best results, treatment should be initiated at the first symptom or sign of an attack; however, nasal spray can be used at any stage of a migraine attack. For further information, consult manufacturer labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Children ≥6 years and Adolescents: May be administered undiluted slowly over 2 to 3 minutes; or diluted and infused over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22049203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22049203'])">Ref</a></span>). Test doses have been administered over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34105158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34105158'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F160444"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">0.5 mg per spray: Assemble nasal sprayer immediately prior to use. Lift tab on vial to bend back blue cover; remove the blue cover and metal seal in a circular motion. Keeping the vial upright, remove rubber stopper and set vial aside. Remove plastic cover from bottom of nasal spray pump unit; screw spray pump onto vial until secure. Remove cap from spray unit, hold vial upright with nasal sprayer pointed away from face, and prime by pumping 4 times. Spray once into each nostril. Do not tilt head back or sniff through nose while spraying or immediately after. Wait 15 minutes and spray once again into each nostril. Dispose nasal spray pump with vial; do not reuse.</p>
<p style="text-indent:-2em;margin-left:4em;">0.725 mg per spray: Assemble nasal sprayer immediately prior to use. Flip up blue plastic vial cover; use vial cover to peel metal foil from gray rubber stopper in circular motion. Metal foil may come off in 2 or more pieces; remove all metal foil. Remove rubber stopper and set vial aside. Holding nasal spray device upright, remove clear plastic cover from base; push glass vial onto bottom of nasal spray device and screw vial onto spray device until secure. Hold assembled nasal sprayer device upright with sprayer pointed away from face; while pressing finger grips down, prime by pressing glass vial up 4 times. Keeping head straight, spray once into each nostril. Dispose nasal spray pump with vial; do not reuse.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion (Ford protocol): Administer as a continuous infusion; refer to indication-specific infusion rates in dosing for detailed recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9100396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9100396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent infusion (Raskin protocol): Administer slowly over 2 to 3 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3520384','lexi-content-ref-2272823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3520384','lexi-content-ref-2272823'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F51769429"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Dihydroergotamine may cause teratogenicity, reproductive toxicity and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">Assess risk to determine appropriate containment strategy (USP-NF 2017). NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (when dosage form allows) closed system transfer devices (CSTDs) for preparation. Double gloves and a protective gown are required during IM, IV or SubQ administration. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016).</p></div>
<div class="block sts drugH1Div" id="F160460"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store below 25°C (77°F); do not refrigerate or freeze. Protect from light and heat.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal spray: Do not refrigerate or freeze. Once applicator has been prepared or vial has been opened, use within 8 hours; discard any unused solution.</p>
<p style="text-indent:-2em;margin-left:4em;">0.5 mg per spray: Store &lt;25°C (&lt;77°F).</p>
<p style="text-indent:-2em;margin-left:4em;">0.725 mg per spray: Store at 20°C to 25°C (68°F to 77°F); excursions allowed between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F56206730"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Trudhesa: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F213436s000lbl.pdf%23page%3D22&amp;token=JffvH85NLhqwHznYIH%2BAdfQs9td8vcFHCOq1wiq0Q8hl3kAC7QjL3KN78P%2Bf%2BH45a75Key3Mz2RLYcQa2TZa%2BtCU0O64bH03hkDPnBynZRfZ4NGW1WCopQSSNo04Le0V&amp;TOPIC_ID=13232" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213436s000lbl.pdf#page=22</a></p></div>
<div class="block usep drugH1Div" id="F53566527"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Acute treatment of migraine headache with or without aura (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Acute treatment of migraine headache with or without aura and cluster headaches (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F56411519"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F160503"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F160435"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may enhance the vasoconstricting effect of Alpha1-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Ergot Derivatives may enhance the adverse/toxic effect of Bromocriptine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the vasoconstricting effect of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the adverse/toxic effect of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: Ergot Derivatives may enhance the vasoconstricting effect of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates) may diminish the vasodilatory effect of Nitroglycerin. Nitroglycerin may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).  Management: Avoid the use of ergot derivatives in patients receiving nitroglycerin for angina (or in any angina patient) if possible. If combined, monitor for decreased effects of nitroglycerin and increased adverse effects of the ergot derivative (eg, ergotism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxithromycin: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F160449"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and published human data, dihydroergotamine may increase the risk of preterm delivery. An increased risk of major congenital malformations or miscarriage has not been reported (Bérard 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). When treatment for acute migraine or cluster headaches in pregnancy is needed, agents other than dihydroergotamine are recommended (ACOG 2022; Bjørk 2021; CHS [Worthington 2013]; Schindler 2022).</p></div>
<div class="block mopp drugH1Div" id="F58921221"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline pregnancy test; cardiovascular evaluation in patients with coronary artery disease (CAD) risk factors (prior to initiation); nausea/vomiting.</p></div>
<div class="block pha drugH1Div" id="F160429"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Efficacy in migraine is attributed to the activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels resulting in vasoconstriction and/or activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system resulting in the inhibition of pro-inflammatory neuropeptide release. Dihydroergotamine binds with high affinity to serotonin 5-HT<sub>1Dα</sub>, 5-HT<sub>1Dβ</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors, noradrenaline α<sub>2A</sub>, α<sub>2B</sub> and α<sub>1</sub> receptors, and dopamine D<sub>2L</sub> and D<sub>3</sub> receptors. Dihydroergotamine also possesses oxytocic properties.</p></div>
<div class="block phk drugH1Div" id="F160446"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~800 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic (one active metabolite, 8'-β-hydroxydihydroergotamine).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: IM, IV: 100%; Intranasal: 40% (Saper 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IM, IV, Intranasal (0.5 mg per spray): ~9 to 10 hours; Intranasal (0.725 mg per spray): 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 24 minutes; IV: 1 to 2 minutes; Intranasal: 30 to 60 minutes (Saper 2006; manufacturer’s labeling); SUBQ 15 to 45 minutes (Schran 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces; urine (6% to 7% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F160451"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Migranal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diergo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dihydergot</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ditamin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Migranal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Neomigran</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dihydergot</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Migranil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Diidergot | Migranal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ditamin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dihydergot</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dihydroergotamine | Dihydroergotamine mesylate | Migranal</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Neomigran</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ditamin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dihydergot</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dihydergot</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31347910">
<a name="31347910"></a>Anderson PO. Migraine drug therapy during breastfeeding. <i>Breastfeed Med</i>. 2019;14(7):445-447. doi:10.1089/bfm.2019.0154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/31347910/pubmed" id="31347910" target="_blank">31347910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34588467">
<a name="34588467"></a>Bérard A, Strom S, Zhao JP, Kori S, Albrecht D. Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes. <i>Sci Rep</i>. 2021;11(1):19302. doi:10.1038/s41598-021-97092-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/34588467/pubmed" id="34588467" target="_blank">34588467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33852763">
<a name="33852763"></a>Bjørk MH, Kristoffersen ES, Tronvik E, Egeland Nordeng HM. Management of cluster headache and other trigeminal autonomic cephalalgias in pregnancy and breastfeeding. <i>Eur J Neurol</i>. 2021;28(7):2443-2455. doi:10.1111/ene.14864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/33852763/pubmed" id="33852763" target="_blank">33852763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-135643">
<a name="135643"></a>Conté JJ, Fournié GJ, Maurette MH. Dihydroergotamine: an effective treatment for postural hypotension due to antihypertensive drugs (ganglion-blocking agents excepted). <i>Cardiology</i>. 1976;61(suppl 1):342-349. doi:10.1159/000169828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/135643/pubmed" id="135643" target="_blank">135643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>D.H.E 45 (dihydroergotamine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gland.1">
<a name="Gland.1"></a>Dihydroergotamine mesylate injection [prescribing information]. Hyderabad, India: Gland Pharma Limited; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perrigo.1">
<a name="Perrigo.1"></a>Dihydroergotamine mesylate injection [prescribing information]. Minneapolis, MN: Perrigo; July 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9100396">
<a name="9100396"></a>Ford RG, Ford KT. Continuous intravenous dihydroergotamine in the treatment of intractable headache. <i>Headache</i>. 1997;37(3):129-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/9100396/pubmed" id="9100396" target="_blank">9100396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8970458">
<a name="8970458"></a>Gallagher RM; Dihydroergotamine Working Group. Acute treatment of migraine with dihydroergotamine nasal spray. <i>Arch Neurol</i>. 1996;53(12):1285-1291. doi:10.1001/archneur.1996.00550120097022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/8970458/pubmed" id="8970458" target="_blank">8970458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garza.1">
<a name="Garza.1"></a>Garza I, Schwedt TJ. Medication overuse headache: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-476438">
<a name="476438"></a>Jennings G, Esler M, Holmes R. Treatment of orthostatic hypotension with dihydroergotamine. <i>Br Med J</i>. 1979;2(6185):307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/476438/pubmed" id="476438" target="_blank">476438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26517974">
<a name="26517974"></a>Kabbouche M. Pediatric Inpatient Headache Therapy: What is Available. <i>Headache</i>. 2015;55(10):1426-1429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/26517974/pubmed" id="26517974" target="_blank">26517974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19125879">
<a name="19125879"></a>Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. <i>Headache</i>. 2009;49(1):106-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/19125879/pubmed" id="19125879" target="_blank">19125879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26788131">
<a name="26788131"></a>Kacperski J, Kabbouche MA, O'Brien HL, Weberding JL. The optimal management of headaches in children and adolescents. <i>Ther Adv Neurol Disord</i>. 2016;9(1):53-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/26788131/pubmed" id="26788131" target="_blank">26788131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2016">
<a name="Kliegman.2016"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7843951">
<a name="7843951"></a>Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. <i>Headache</i>. 1994;34(10):578-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/7843951/pubmed" id="7843951" target="_blank">7843951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Migergot.1">
<a name="Migergot.1"></a>Migergot (ergotamine tartrate and caffeine) [prescribing information]. Glendale, WI: Crealta Pharmaceuticals LLC; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Migranal.1">
<a name="Migranal.1"></a>Migranal (dihydroergotamine mesylate) nasal spray [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22049203">
<a name="22049203"></a>Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. <i>Neurology</i>. 2011;77(20):1827-1832. doi:10.1212/WNL.0b013e3182377dbb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/22049203/pubmed" id="22049203" target="_blank">22049203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842580">
<a name="20842580"></a>O'Brien HL, Kabbouche MA, Hershey AD. Treatment of acute migraine in the pediatric population. <i>Curr Treat Options Neurol</i>. 2010;12(3):178-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/20842580/pubmed" id="20842580" target="_blank">20842580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25617222">
<a name="25617222"></a>O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. <i>Curr Treat Options Neurol</i>. 2015;17(1):326. doi:10.1007/s11940-014-0326-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/25617222/pubmed" id="25617222" target="_blank">25617222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26790849">
<a name="26790849"></a>Patniyot IR, Gelfand AA. Acute treatment therapies for pediatric migraine: a qualitative systematic review. <i>Headache</i>. 2016;56(1):49-70. doi:10.1111/head.12746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/26790849/pubmed" id="26790849" target="_blank">26790849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3520384">
<a name="3520384"></a>Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. <i>Neurology</i>. 1986;36(7):995-997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/3520384/pubmed" id="3520384" target="_blank">3520384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2272823">
<a name="2272823"></a>Raskin NH, "Treatment of Status Migrainosus: The American Experience," <i>Headache</i>, 1990, 30(Suppl 2):550-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/2272823/pubmed" id="2272823" target="_blank">2272823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2886820">
<a name="2886820"></a>Reginald PW, Beard RW, Kooner JS, et al. Intravenous dihydroergotamine to relieve pelvic congestion with pain in young women. <i>Lancet</i>. 1987;2(8555):351-353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/2886820/pubmed" id="2886820" target="_blank">2886820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2954090">
<a name="2954090"></a>Saïd G. Action of dihydroergotamine in severe orthostatic hypotension. 16 cases. <i>Presse Med</i>. 1987;16(17):800-803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/2954090/pubmed" id="2954090" target="_blank">2954090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17078849">
<a name="17078849"></a>Saper JR and Silberstein S, “Pharmacology of Dihydroergotamine and Evidence of Efficacy and Safety in Migraine,” <i>Headache</i>, 2006, 46(Suppl 4):171-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/17078849/pubmed" id="17078849" target="_blank">17078849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35296510">
<a name="35296510"></a>Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. <i>BMJ</i>. 2022;376:e059577. doi:10.1136/bmj-2020-059577<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/35296510/pubmed" id="35296510" target="_blank">35296510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3988387">
<a name="3988387"></a>Schran HF and Tse FL, “Pharmacokinetics of Dihydroergotamine Following Subcutaneous Administration in Humans,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1985, 23(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/3988387/pubmed" id="3988387" target="_blank">3988387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2370132">
<a name="2370132"></a>Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. <i>Headache</i>. 1990;30(6):334-339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/2370132/pubmed" id="2370132" target="_blank">2370132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1446987">
<a name="1446987"></a>Silberstein SD, Silberstein JR. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE. <i>Headache</i>. 1992;32(9):439-445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/1446987/pubmed" id="1446987" target="_blank">1446987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34363701">
<a name="34363701"></a>Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>®</sup>) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. <i>Headache</i>. 2021;61(8):1214-1226. doi:10.1111/head.14184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/34363701/pubmed" id="34363701" target="_blank">34363701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34105158">
<a name="34105158"></a>Srouji R, Schenkel SR, Forbes P, Cahill JE. Dihydroergotamine infusion for pediatric refractory headache: a retrospective chart review. <i>Headache</i>. 2021;61(5):777-789. doi:10.1111/head.14117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/34105158/pubmed" id="34105158" target="_blank">34105158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2877953">
<a name="2877953"></a>Thulesius O, Berlin E. Dihydroergotamine therapy in orthostatic hypotension due to psychotropic drugs. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1986;24(9):465-467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/2877953/pubmed" id="2877953" target="_blank">2877953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trudhesa.1">
<a name="Trudhesa.1"></a>Trudhesa (dihydroergotamine mesylate) [prescribing information]. Seattle, WA: Impel NeuroPharma Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed August 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8639069">
<a name="8639069"></a>Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.<i> Arch Neurol</i>. 1996;53(2):180-184. doi:10.1001/archneur.1996.00550020092020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/8639069/pubmed" id="8639069" target="_blank">8639069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13232 Version 370.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
